Joseph Podolski, Board Member


Mr. Podolski has over 37 years experience in the pharmaceutical and biotech industry. He is the former President and CEO of Repros Therapeutics (formerly Zonagen) and has been with this company since 1989 (retired in 2017). Following his promotion to President and CEO in 1992, he was instrumental in taking Repros public the following year after he redirected the efforts of the company from animal health into human reproductive health.

He has led the Repros Therapeutics clinical development programs and has taken drug candidates through the entire regulatory process from preclinical safety studies to NDA submission. He acquired the sexual dysfunction technology that eventually led to the product Vasomax® and subsequently spearheaded both the clinical program and the out-licensing effort leading to a $70+ million follow-on offering and a partnership with Schering Plough. He is named as the inventor of the technology surrounding the company's Androxal Program and two of the second generation impotence therapies and championed the efforts leading to the licensing of the NIH selective progesterone receptor modulators.

Mr. Podolski has successfully raised over $160 million for Repros in both the public and private US capital markets, successfully negotiating four out-licensing deals. In December of 2003, he reorganized the capital structure of the company via a “modified Dutch tender auction” which placed control of the company with its current shareholders.

Prior to joining Repros, Mr. Podolski held positions in operations, engineering, quality control, research and product development at Baxter, Abbott and G. D. Searle.

He holds a M.S. degree in Chemical Engineering from Illinois Institute of Technology and has an in-depth working knowledge of the process surrounding intellectual property evolution. He is named as the inventor on 13 issued US patents and numerous applications

and concepts.

Jerry R. Youkey, MD Board Member, Chairman


Dr. Jerry R. Youkey joined the Greenville Hospital System in 1998 and currently serves as Vice President of Medical and Academic Services, reporting to the CEO. The Greenville Hospital System employs approximately 9,000 employees and 1,000 medical doctors.

Dr. Youkey served a rotating internship and general surgery residency at William Beaumont Army Medical Center, El Paso, Texas and a fellowship in peripheral vascular surgery at Walter Reed Army Medical Center, Washington, DC. He also served in the United States Army and was honorably discharged in August of 1984, attaining the rank of Lieutenant Colonel, Medical Corps. Dr. Youkey served as Chief, Department of Surgery, and Director, Peripheral Vascular Surgery Fellowship program at Geisinger Medical Center, Danville, PA, prior to his arrival in Greenville. He is certified by the American Board of Surgery in general surgery and general vascular surgery.

He is widely published in his specialty field of general vascular surgery, having authored books, abstracts, and journal articles. He holds the academic appointment of Professor and Associate Dean at the University of South Carolina, Columbia, SC, and the Medical University of South Carolina, Charleston, SC. In addition to his administrative duties, Dr. Youkey practices general vascular surgery at the Greenville Hospital System, Greenville, SC. He received his Bachelor of Arts degree from Stanford University, Palo Alto, CA, his medical degree from Marquette Medical School, Milwaukee, WI, and is a member of numerous professional societies and organizations.

​Michael T. Redman, CEO & Board Member


Mr. Redman is the chief executive officer of Oncolix, Inc. and has served in this position since formation of the company in November of 2006.

Prior to Oncolix, Mr. Redman was the CEO of Bone Medical, a public company focused in the area of oral peptide delivery of products related to musculoskeletal disorders. Immediately prior to Bone Medical, Mr. Redman was the CEO and co-founder of Opexa Pharmaceuticals, which commenced operations in February of 2001 and was successfully sold to PharmaFrontiers Corporation in November of 2004. PharmaFrontiers later reorganized the company, which is now named Opexa Therapeutics, a NASDAQ-listed company.

His career spans over 25 years in the pharmaceuticals and biotechnology industry and encompasses leadership in sales, marketing, business and commercial development. In addition to the three companies in which he served as CEO, Mr. Redman also held key management positions with Zonagen, Aronex Pharmaceuticals, Biovail, and

American Home Products.

Mr. Redman has been instrumental in closing multiple pharmaceutical licensing deals, both domestic and international. These deals include in-licensing of university and NIH intellectual property, acquisitions and divestitures. He is an active member of the Licensing Executives Society and formerly served on its Executive Committee. Mr. Redman earned a BA in Biology from the University of Missouri and a Masters in Business Administration from the

University of Phoenix.


Board Members

Dale Zajicek, Board Member

Mr. Zajicek has over 37 years of experience in the pharmaceutical and biotech industry. In 2015 he retired as President of BioVectra, Inc., located in Charlottetown, Prince Edward Island, Canada, and was with this company since 1995. Following his promotion to Chief Operating Officer in 2005, he has been responsible for significant growth of the firm’s contract manufacturing and drug development efforts, with the firm filing numerous Drug Master Files (DMF), Investigational New Drug applications (IND), and supported the New Drug Applications for numerous clients.

Mr. Zajicek successfully led BioVectra to the development of generic docetaxel, and obtained first to file status for this $1 billion annual sales oncology drug. BioVectra successfully partnered the product with Sandoz for the US market, and other marketing firms for markets in Canada, Europe, Middle East, North Africa, and South America. BioVectra is engaged with clients and partners on several clinical phase, pre-commercial, and commercial opportunities. Under Mr. Zajicek’s leadership, BioVectra has developed capabilities in microbial fermentation for protein-based and small molecule drugs, as well as combining biotech processing with synthetic capabilities to perform unique chemistries and conjugations of large to small molecules.

Prior to joining BioVectra, Mr. Zajicek held positions in manufacturing operations, engineering, research and product development, and business development at G. D. Searle and The NutraSweet Company.

He holds a BS in Chemical Engineering from Illinois Institute of Technology and a BS in Business Administration from Elmhurst College. He has an in-depth working knowledge of the process development and commercial processing.